CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新型抗癌药物的分子生物学：聚焦激酶抑制剂、生物制品与 CAR-T 细胞治疗
英文原题：Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.
查看英文原题
Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究思路按摘要原文分段
背景
近年来，随着针对免疫系统的新型治疗方法的引入，癌症治疗发生了重大变化。
目的
本综述的目的是讨论新型抗癌药物，包括激酶抑制剂、生物制剂和CAR-T 细胞疗法。
方法
最近的研究文章通过关键词如“激酶抑制剂”、“CAR-T 细胞疗法”从PubMed中提取。结果与讨论：激酶抑制剂的数量显著增加，因为它们在生物制品联合治疗中显示出有效性。CAR-T 代表了该领域的重大突破。此外，研究还关注了它们的作用机制以及单独使用或联合使用的合理性，与其作用方式相关。
展开英文摘要原文
OBJECTIVES
The objective of this review is to discuss novel anticancer drugs including kinase inhibitors, biologics and cellular therapy with CAR-T cells.
METHODS
Most recent research articles were extracted from PubMed using keywords such as "kinases inhibitors", "CAR-T cell therapy". RESULTS AND DISCUSSION: The number of kinase inhibitors is significantly increasing due to their demonstrated effectiveness in combination with biologics. CAR-T represented a major breakthrough in the field. Also, it focused on their mechanisms of action and the rational of their use either alone or in combination in relation to their modes of action.
论文信息
- 作者
- Abdo EL、Ajib I、El Mounzer J、Husseini M、Kalaoun G、Matta TM、Mosleh R、Nasr F
- 第一作者单位
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, Room 4722, P.O. Box 36, Byblos, Lebanon.
- 通讯作者单位
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, Room 4722, P.O. Box 36, Byblos, Lebanon. wissam.faour@lau.edu.lb.
- 文献类型
- 综述
- 期刊
- Inflammation research : official journal of the European Histamine Research Society ... [et al.]2025 Feb 17
- 原文标识
- PubMed 39960501 · DOI 10.1007/s00011-025-02008-5